Treatment Options in the Relapsed/Refractory Setting

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.